Berger Financial Group Inc Has $6.91 Million Position in Cencora, Inc. $COR

Berger Financial Group Inc lifted its holdings in Cencora, Inc. (NYSE:COR) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,056 shares of the company’s stock after acquiring an additional 113 shares during the period. Berger Financial Group Inc’s holdings in Cencora were worth $6,913,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in COR. AMF Tjanstepension AB lifted its position in shares of Cencora by 44.5% during the 2nd quarter. AMF Tjanstepension AB now owns 112,643 shares of the company’s stock valued at $33,782,000 after acquiring an additional 34,687 shares during the period. LGT Fund Management Co Ltd. boosted its position in shares of Cencora by 15.6% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 12,323 shares of the company’s stock worth $3,695,000 after purchasing an additional 1,666 shares in the last quarter. 111 Capital acquired a new stake in shares of Cencora in the 2nd quarter valued at about $313,000. QRG Capital Management Inc. increased its position in Cencora by 2.1% in the 2nd quarter. QRG Capital Management Inc. now owns 20,646 shares of the company’s stock valued at $6,191,000 after buying an additional 431 shares in the last quarter. Finally, Stock Yards Bank & Trust Co. boosted its holdings in Cencora by 4.8% in the second quarter. Stock Yards Bank & Trust Co. now owns 1,387 shares of the company’s stock worth $416,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $302.54 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a 50-day moving average of $294.68 and a 200-day moving average of $290.25. Cencora, Inc. has a one year low of $218.65 and a one year high of $315.23. The company has a market cap of $58.66 billion, a P/E ratio of 31.13, a P/E/G ratio of 1.41 and a beta of 0.63.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion for the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.34 EPS. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s payout ratio is presently 22.63%.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the transaction, the chief executive officer owned 39,274 shares of the company’s stock, valued at $11,389,460. The trade was a 11.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock valued at $16,292,923 over the last three months. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on COR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a research report on Saturday, September 27th. Wells Fargo & Company raised their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Jefferies Financial Group lifted their price objective on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Finally, Morgan Stanley set a $330.00 target price on shares of Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Ten research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average price target of $311.25.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.